One of India's solutions to get lower-cost meds for its impoverished and uninsured--compulsory licenses--has ignited drugmakers' ire. And with an Indian committee currently assessing a batch of patented drugs as compulsory licensing candidates, the U.S. is fighting back--politely, at least so far.
An EU drug-review committee recommended Teva Pharmaceutical Industries' knockoff version of the AstraZeneca respiratory med Symbicort on Friday. With key patents already expired, Teva's DuoResp Spiromax could soon put AstraZeneca's brand under siege.
Teva Pharmaceutical Industries and Ranbaxy Laboratories only have to pay $300,000 in a new "pay-for-delay" settlement with the state of New York over their arrangement on generic Lipitor. But the agreement also prevents the two from sidestepping each other on dozens of other drugs, opening up the possibility of greater generic competition.
Sanofi's got the top-selling diabetes drug in the world right now, and it intends to keep it that way. The French drugmaker is suing Eli Lilly over infringement claims on four of the patents for its Lantus insulin product, which is set to lose protection next February.
First, South Africa proposed patent-law changes that would help foster generic drugs. Then, Big Pharma and its smaller colleagues in the country's pharma association hatched a counter-offensive: a $600,000 lobbying campaign against the measure. Now, Novo Nordisk has quit that group, the Innovative Pharmaceutical Association of South Africa (Ipasa), in protest.
Teva Pharmaceutical Industries is making one last desperate plea to the U.S. Supreme Court. The Israel-based drugmaker has asked SCOTUS to review a lower court's decision to invalidate key patents on its top-selling drug, Copaxone.
Patent-cliff worries have been weighing on Allergan as of late, but a Texas judge has allayed some of those concerns--at least for now. That judge upheld U.S. patents covering glaucoma treatment Lumigan on Tuesday, the same day U.S. patent officials issued Allergan new protection for its leading product, Restasis.
If you need more evidence that Big Pharma patents and trademarks are under siege in emerging markets, here's this: China yanked Johnson & Johnson's OneTouch trademark rights, allowing competitors to sell their diabetes-monitoring products under the same name.
Pharma-academic partnerships have their pitfalls--and how to share the cash is one of the biggest. Case in point: Boston Children's Hospital's lawsuit against Celgene ($CELG), which makes several lucrative cancer treatments.
Earlier this week, when Hanmi Pharmaceutical launched its Nexium copy in the U.S. at-risk, it faced the possibility of paying a high price if AstraZeneca won a bid to defend its patent. An appeals court ruling in Hanmi's favor has let it off the hook, at least for now. If AstraZeneca wants to collect, it will have to convince the Supreme Court to hear the case--and it will have to win.